Cargando…
TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
Immunotherapy with checkpoint inhibitors, such as PD-1/PD-L1 blockage, is becoming standard of practice for an increasing number of cancer types. However, the response rate is only 10%-40%. Thus, identifying biomarkers that could accurately predict the ICI-therapy response is critically important. W...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004558/ https://www.ncbi.nlm.nih.gov/pubmed/35344507 http://dx.doi.org/10.18632/aging.203980 |